Home/Pipeline/TYK-201

TYK-201

Hematological Malignancies

PreclinicalActive

Key Facts

Indication
Hematological Malignancies
Phase
Preclinical
Status
Active
Company

About TYK Medicines

A clinical-stage biotech developing targeted small molecule therapies for oncology and immunology through structure-based drug design.

View full company profile

Therapeutic Areas

Other Hematological Malignancies Drugs

DrugCompanyPhase
NST-201 (estimated)Novastage PharmaceuticalsPreclinical/IND-enabling
TNB-655Tenacia BiotechnologyPreclinical
Undisclosed CAR-T ProgramOBiO TechnologyPhase 1/2
NP-G2-044Novita PharmaceuticalsPhase 2a
PS-102Perimeter Systems, Inc.Preclinical
JaxBio Hematology Cancer TestJaxBioPreclinical
YZY-002YZY BiopharmaPhase 1